Boston Biomedica Announces Development of Novel Sample Processing Procedure

Proprietary Process Using PCT to be Presented at Boston Genomics Conference



Apr 26, 2001, 01:00 ET from Boston Biomedica, Inc.

    WEST BRIDGEWATER, Mass., April 26 /PRNewswire/ -- Boston Biomedica, Inc.
 (Nasdaq: BBII) announced today that Dr. Feng Tao, Project Scientist in the
 Company's Pressure Cycling Technology (PCT) research group, will present data
 this afternoon at Cambridge Healthtech Institute's Genomic Sample Preparation
 Conference in Boston on BBI's novel system for the extraction of nucleic acids
 (DNA and RNA) from cells and tissues.  Dr. Tao's talk, entitled Pressure
 Cycling Technology (PCT)-Based Nucleic Acid Sample Preparation for Diagnostics
 and Genomics, will address a new method for releasing nucleic acids from a
 variety of biological samples.  The system combines Boston Biomedica's
 patented PCT technology with patent-pending devices to efficiently prepare
 nucleic acid samples from cells and tissues.  This process represents a new
 and exciting approach to solving a difficult laboratory problem, and offers
 potentially important advantages for proteomics and nucleic acid testing in
 many fields, including research and industrial applications in agriculture,
 medicine, pharmaceuticals and biotechnology.
     The PCT sample preparation system utilizes a unique combination of
 pressure and temperature in BBI's ultra-high pressure BAROCYCLER(TM)
 instrument to efficiently release cellular contents while maintaining the
 integrity and biological activity of the molecules liberated, and in
 significantly less time than standard laboratory techniques.  Since this
 process does not require the use of detergents or harsh chemicals, the initial
 product can be used directly as a source of nucleic acids for many research
 applications, or can be further processed to obtain more highly purified
 materials. The products prepared by the PCT sample processing system can also
 be used for analysis and purification of other biological molecules such as
 proteins, carbohydrates, lipids and various metabolites.
     "Our novel PCT sample processing system generates high quality cellular
 component preparations in a few minutes, thus eliminating the slow and labor-
 intensive methods commonly used for hard-to-lyse cell and tissue sample
 processing," commented Richard T. Schumacher, Founder, CEO, and Chairman of
 Boston Biomedica.  "We are very excited by the results of these studies, and
 believe that this work may lead to the release of our first commercial PCT
 product."
     Boston Biomedica, Inc. provides products and services for the detection
 and monitoring of infectious diseases such as AIDS and Viral Hepatitis. BBI
 has three operating business units: (1) BBI Diagnostics, an ISO 9001 certified
 manufacturer and supplier of quality control and diagnostics reagents used to
 increase the accuracy of in vitro diagnostic tests, (2) BBI Biotech Research
 Laboratories, a research and development center providing R&D support for the
 other BBI business units, as well as contract research and repository services
 for the government, industry and other third parties, and (3) BBI Source
 Scientific, an ISO 9001 certified manufacturer of diagnostic instrumentation
 and medical devices.  In addition, BBI is conducting research and development
 in Pressure Cycling Technology (PCT) through its subsidiary BBI BioSeq, with
 the goal of introducing new solutions for a number of important healthcare
 issues, including: inactivation of pathogens in human plasma, extraction of
 nucleic acids, food safety, and genomics.  BBI also maintains a passive
 investment in Panacos Pharmaceuticals, a privately held antiviral drug and
 vaccine development company recently spun-out from BBI, whose goal is to
 introduce new solutions for the treatment of infectious diseases.
     Statements contained in this news release that state the Company's or
 management's intention, hopes, beliefs, expectations or predictions of the
 future are "forward-looking" statements.  It is important to note that the
 Company's actual results could differ materially from those projected in such
 forward-looking statements.  Factors that could cause actual results to differ
 from those projected include the possibility that, due to difficulties in the
 development of the technology, BBI may not be successful in developing
 pressure cycling technology into commercially viable products or services;
 that the PCT sample processing system may never become a better alternative
 than current methods for biomolecular purification or nucleic acid isolation;
 that pressure cycling technology may not be adaptable to any other
 commercially viable applications; that certain pressure cycling applications
 may not fall within the claims of the Company's four issued patents; and that
 individuals and groups utilizing such PCT procedures may not be required to
 license such technology from BBI.  Additional information concerning factors
 that could cause actual results to differ materially from those in the
 forward-looking statements is contained from time to time in the Company's SEC
 filing including, but not limited to, the Company's annual report on Form 10-K
 for the year ended December 31, 2000 and quarterly reports on Form 10-Q for
 the periods ended March 31, June 30 and September 30, 2000.  Copies of these
 documents may be obtained by contacting the Company or the SEC.
     Visit us at our website http://www.bbii.com
     Please email us at IR@bbii.com if you prefer to receive future
 announcements electronically
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X73215386
 
 

SOURCE Boston Biomedica, Inc.
    WEST BRIDGEWATER, Mass., April 26 /PRNewswire/ -- Boston Biomedica, Inc.
 (Nasdaq: BBII) announced today that Dr. Feng Tao, Project Scientist in the
 Company's Pressure Cycling Technology (PCT) research group, will present data
 this afternoon at Cambridge Healthtech Institute's Genomic Sample Preparation
 Conference in Boston on BBI's novel system for the extraction of nucleic acids
 (DNA and RNA) from cells and tissues.  Dr. Tao's talk, entitled Pressure
 Cycling Technology (PCT)-Based Nucleic Acid Sample Preparation for Diagnostics
 and Genomics, will address a new method for releasing nucleic acids from a
 variety of biological samples.  The system combines Boston Biomedica's
 patented PCT technology with patent-pending devices to efficiently prepare
 nucleic acid samples from cells and tissues.  This process represents a new
 and exciting approach to solving a difficult laboratory problem, and offers
 potentially important advantages for proteomics and nucleic acid testing in
 many fields, including research and industrial applications in agriculture,
 medicine, pharmaceuticals and biotechnology.
     The PCT sample preparation system utilizes a unique combination of
 pressure and temperature in BBI's ultra-high pressure BAROCYCLER(TM)
 instrument to efficiently release cellular contents while maintaining the
 integrity and biological activity of the molecules liberated, and in
 significantly less time than standard laboratory techniques.  Since this
 process does not require the use of detergents or harsh chemicals, the initial
 product can be used directly as a source of nucleic acids for many research
 applications, or can be further processed to obtain more highly purified
 materials. The products prepared by the PCT sample processing system can also
 be used for analysis and purification of other biological molecules such as
 proteins, carbohydrates, lipids and various metabolites.
     "Our novel PCT sample processing system generates high quality cellular
 component preparations in a few minutes, thus eliminating the slow and labor-
 intensive methods commonly used for hard-to-lyse cell and tissue sample
 processing," commented Richard T. Schumacher, Founder, CEO, and Chairman of
 Boston Biomedica.  "We are very excited by the results of these studies, and
 believe that this work may lead to the release of our first commercial PCT
 product."
     Boston Biomedica, Inc. provides products and services for the detection
 and monitoring of infectious diseases such as AIDS and Viral Hepatitis. BBI
 has three operating business units: (1) BBI Diagnostics, an ISO 9001 certified
 manufacturer and supplier of quality control and diagnostics reagents used to
 increase the accuracy of in vitro diagnostic tests, (2) BBI Biotech Research
 Laboratories, a research and development center providing R&D support for the
 other BBI business units, as well as contract research and repository services
 for the government, industry and other third parties, and (3) BBI Source
 Scientific, an ISO 9001 certified manufacturer of diagnostic instrumentation
 and medical devices.  In addition, BBI is conducting research and development
 in Pressure Cycling Technology (PCT) through its subsidiary BBI BioSeq, with
 the goal of introducing new solutions for a number of important healthcare
 issues, including: inactivation of pathogens in human plasma, extraction of
 nucleic acids, food safety, and genomics.  BBI also maintains a passive
 investment in Panacos Pharmaceuticals, a privately held antiviral drug and
 vaccine development company recently spun-out from BBI, whose goal is to
 introduce new solutions for the treatment of infectious diseases.
     Statements contained in this news release that state the Company's or
 management's intention, hopes, beliefs, expectations or predictions of the
 future are "forward-looking" statements.  It is important to note that the
 Company's actual results could differ materially from those projected in such
 forward-looking statements.  Factors that could cause actual results to differ
 from those projected include the possibility that, due to difficulties in the
 development of the technology, BBI may not be successful in developing
 pressure cycling technology into commercially viable products or services;
 that the PCT sample processing system may never become a better alternative
 than current methods for biomolecular purification or nucleic acid isolation;
 that pressure cycling technology may not be adaptable to any other
 commercially viable applications; that certain pressure cycling applications
 may not fall within the claims of the Company's four issued patents; and that
 individuals and groups utilizing such PCT procedures may not be required to
 license such technology from BBI.  Additional information concerning factors
 that could cause actual results to differ materially from those in the
 forward-looking statements is contained from time to time in the Company's SEC
 filing including, but not limited to, the Company's annual report on Form 10-K
 for the year ended December 31, 2000 and quarterly reports on Form 10-Q for
 the periods ended March 31, June 30 and September 30, 2000.  Copies of these
 documents may be obtained by contacting the Company or the SEC.
     Visit us at our website http://www.bbii.com
     Please email us at IR@bbii.com if you prefer to receive future
 announcements electronically
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X73215386
 
 SOURCE  Boston Biomedica, Inc.